文献速递呼吸危重症与机械通气

新型抗TNFR1结构域抗体在实验性急性肺损伤中预防肺部炎症

Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury.
PubMed 文献 · Thorax · 2018-01-29

本研究开发了选择性TNFR1拮抗剂GSK1995057(结构域抗体),在体外、非人灵长类急性肺损伤模型及37名健康受试者中评估其效果。在健康人中,雾化吸入GSK1995057可减轻内毒素诱导的肺中性粒细胞增多、炎症因子释放及内皮损伤迹象,支持其作为预防ARDS的潜在疗法。

要点

  • 选择性抑制TNFR1可减轻体外内皮细胞炎症反应及非人灵长类急性肺损伤。
  • 健康受试者雾化吸入GSK1995057后,内毒素诱导的肺部炎症和内皮损伤显著减轻。
  • 该策略可能为预防急性呼吸窘迫综合征提供新途径。

核心结论

  • 选择性TNFR1结构域抗体GSK1995057经雾化吸入可减轻实验性急性肺损伤中的肺部炎症,支持其预防ARDS的潜力。

研究设计与样本

  • 体外研究:人肺微血管内皮细胞(HMVEC-L)。
  • 体内研究:非人灵长类急性肺损伤模型,雾化吸入GSK1995057预处理。
  • 临床试验:随机对照试验,37名健康受试者接受单次雾化GSK1995057后吸入内毒素。

主要发现

  • 体外:GSK1995057抑制活化HMVEC-L单层细胞因子和中性粒细胞黏附分子表达(P<0.01和P<0.001)。
  • 非人灵长类:GSK1995057显著减轻炎症和肺损伤迹象(所有P<0.01)。
  • 健康人:GSK1995057减轻支气管肺泡灌洗液和血清中的肺中性粒细胞增多、炎症因子释放(所有P<0.01)及内皮损伤迹象(P<0.05)。

临床怎么用

  • 雾化吸入选择性TNFR1拮抗剂可能成为预防急性呼吸窘迫综合征的新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine with both injurious and protective functions, which are thought to diverge at the level of its two cell surface receptors, TNFR1 and TNFR2. In the setting of acute injury, selective inhibition of TNFR1 is predicted to attenuate the cell death and inflammation associated with TNF-α, while sparing or potentiating the protective effects of TNFR2 signalling. We developed a potent and selective antagonist of TNFR1 (GSK1995057) using a novel domain antibody (dAb) therapeutic and assessed its efficacy in vitro, in vivo and in a clinical trial involving healthy human subjects. METHODS: We investigated the in vitro effects of GSK1995057 on human pulmonary microvascular endothelial cells (HMVEC-L) and then assessed the effects of pretreatment with nebulised GSK1995057 in a non-human primate model of acute lung injury. We then tested translation to humans by investigating the effects of a single nebulised dose of GSK1995057 in healthy humans (n=37) in a randomised controlled clinical trial in which subjects were subsequently exposed to inhaled endotoxin. RESULTS: Selective inhibition of TNFR1 signalling potently inhibited cytokine and neutrophil adhesion molecule expression in activated HMVEC-L monolayers in vitro (P<0.01 and P<0.001, respectively), and also significantly attenuated inflammation and signs of lung injury in non-human primates (P<0.01 in all cases). In a randomised, placebo-controlled trial of nebulised GSK1995057 in 37 healthy humans challenged with a low dose of inhaled endotoxin, treatment with GSK1995057 attenuated pulmonary neutrophilia, inflammatory cytokine release (P<0.01 in all cases) and signs of endothelial injury (P<0.05) in bronchoalveolar lavage and serum samples. CONCLUSION: These data support the potential for pulmonary delivery of a selective TNFR1 dAb as a novel therapeutic approach for the prevention of acute respiratory distress syndrome. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01587807.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Proudfoot A, Bayliffe A, O'Kane CM, et al. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax. 2018. PMID: 29382797. doi:10.1136/thoraxjnl-2017-210305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。